SMAD3 and glioblastoma: Further, we discovered that APOC1 inhibition downregulates TGFβ2 and disrupts its associated downstream SMAD3 and pSMAD3, revealing a new signaling pathway involving the miR-660-3p/APOC1/TGFβ2 axis in the development of glioblastoma.